复宏汉霖中小股东反对公司被私有化,复星医药并购计划搁置

第一财经
22 Jan

去年以来,医药行业兴起了一波并购潮,但并购牵涉不同利益方的博弈,并购失败的案例逐渐增多。  2025年1月22日晚间,复星医药(600196.SH、02196.HK)私有化复宏汉霖(02696.HK)计划搁置的消息传来。复星医药表示,复宏汉霖将保留H股上市地位。  私有化失败  2024年6月24日,复星医药抛出了一则关于拟以不超过约54.07亿港元私有化复宏汉霖计划。  复宏汉霖是复星医药的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10